Creative Biolabs Introduces Autoantibody Services to Progress Autoimmunity Research
New York, USA – November 1, 2023 – As the medical community grapples with the ongoing global pandemic, the importance of vaccines has been brought to the forefront of public discourse, as have the studies on early disease diagnosis.
“At Creative Biolabs, we share the vision of a world in which disease is minimized and early detection is prioritized. That’s why we’re excited to announce the launch of our comprehensive autoantibody services.” According to a scientist at Creative Biolabs.
The immune system produces autoantibodies that target a person’s own tissues and cells and are crucial for the body’s typical physiological operation. Changes to natural autoantibody (NAA) levels can indicate the early onset of a range of diseases, including autoimmune diseases, neurological disorders, and cancer.
“Our NAA solution aims to improve the understanding of autoantibodies-their role in the body and, more importantly, their potential use in early disease diagnosis.” Noted the scientist.
Creative Biolabs offers a wide range of innovative and comprehensive services to support the detection and analysis of autoantibodies, of which the NAA profiling pipelines are a typical representative, which are designed to meticulously detect and quantify autoantibodies in serum samples-by tracking changes in self-antigen or autoepitope levels that may indicate the early onset of disease.
Highly sensitive and throughput as it can be, the autoantigen microarray performed at Creative Biolabs integrates state-of-the-art equipment to tailor-make the microarrays for detecting and analyzing specific recombinant proteins or peptides in the test sera, body fluid, and antibody, allowing for autoantigen general survey and the research on neurological disorders, cancers, and autoimmunity.
Creative Biolabs can customize autoantibody microarrays to detect diverse self-antigens like nuclear components, cytoplasmic proteins, phospholipid proteins, cell matrix proteins, and tissue-specific proteins to quantify IgG, IgM, IgA, and IgE autoantibodies from serum or other body fluids, thereby facilitating the identification of biomarkers and disease prediction and diagnosis.
“Overall, our NAA services provide a vital tool to advance the early detection and diagnosis of diseases, thereby facilitating personalized and effective treatment plans.” Summarized the scientist.
For more information on Creative Biolabs’ NAA Services, please visit https://www.creative-biolabs.com/natural-autoantibody.
Company Overview
Creative Biolabs is committed to supporting the medical community in the fight against diseases. The team of scientists is excited to collaborate with researchers and medical professionals worldwide to unlock the true potential of autoantibodies in improving patient outcomes.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/natural-autoantibody
